FWP Key Statistics, Chart & Performance
The current stock price of FWP is 1.95 USD. In the past month the price decreased by -35%. In the past year, price decreased by -67.34%.
FWP Technical Analysis
FWP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FWP. FWP has a great financial health rating, but its profitability evaluates not so good.
FWP Financial Highlights
Over the last trailing twelve months FWP reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS increased by 71.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
FWP Forecast & Estimates
FWP Ownership
About FWP
Company Profile
Forward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. The firm granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The firm has the opportunity to receive royalties from Biogen on Biogen’s net sales of Tecfidera or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the 355 Patent Opposition Proceeding, including any appeal thereto.
Company Info
FORWARD PHARMA A/S-ADR
Oestergade 24A, 1, Copenhagen K
COPENHAGEN 1100 DK
CEO: Claus Bo Svendsen
Employees: 4
Phone: 4533444242.0
FORWARD PHARMA A/S-ADR / FWP FAQ
Can you describe the business of FORWARD PHARMA A/S-ADR?
Forward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. The firm granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The firm has the opportunity to receive royalties from Biogen on Biogen’s net sales of Tecfidera or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the 355 Patent Opposition Proceeding, including any appeal thereto.
Can you provide the latest stock price for FORWARD PHARMA A/S-ADR?
The current stock price of FWP is 1.95 USD. The price increased by 7.73% in the last trading session.
What is the dividend status of FORWARD PHARMA A/S-ADR?
FWP does not pay a dividend.
How is the ChartMill rating for FORWARD PHARMA A/S-ADR?
FWP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Would investing in FORWARD PHARMA A/S-ADR be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on FWP.
Can you provide the number of employees for FORWARD PHARMA A/S-ADR?
FORWARD PHARMA A/S-ADR (FWP) currently has 4 employees.